Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Engaged in the discovery, development, and commercialization of innovative pharmaceuticals for the treatment of many diseases, either directly or indirectly. Directly treating a disease would involve some sort of drug that could attack the infection itself. An indirect treatment may involve a drug that's used to enhance the body's own antibody production so those antibodies can attack the infection themselves. Not only do some of these companies develop drugs for human use, a good number of them also work on animal or plant diseases as well.
|
| Totals |
Company |
Industry |
| Sales: |
$16,966.6 Mil |
$103,380.7 Mil |
| Market Cap: |
$113,845.7 Mil |
$391,710.7 Mil |
| Analysts Recommendation: |
Buy |
Buy |
|
|
| Averages |
Company |
Industry |
 |
| Growth |
| Historic Revenue: |
2.1% |
46.3% |
| Estimated Revenue: |
5.5% |
473.1% |
| Historic Earnings: |
9.3% |
(63.9%) |
| Estimated Earnings: |
4.7% |
30.1% |
| Stock Price (1 Year): |
(3.4%) |
23.3% |
| Cash per Share: |
6.6% |
25.7% |
| Dividend: |
N/A |
N/A |
| Price |
| Trailing PE: |
N/A |
N/A |
| Forward PE: |
18.6 |
40.2 |
| Price-to-Sales: |
6.6 |
N/A |
| Price-to-Book: |
15.2 |
7.2 |
| Dividend Yield: |
N/A |
N/A |
| Market Cap: |
$113,845.7 Mil |
$13,057.0 Mil |
| Operations |
| Net Margin: |
36.0% |
(219.8%) |
| Gross Margin: |
84.2% |
83.3% |
| Return on Equity: |
.8 |
(1.5) |
| Return on Assets: |
.4 |
(.2) |
| Balance Sheet |
| Current Ratio: |
1.3 |
5.5 |
| Quick Ratio: |
1.0 |
5.3 |
| Cash Ratio: |
.4 |
4.7 |
| Debt-to-Equity: |
1.1 |
2.8 |
| Interest Coverage: |
.8 |
.7 |
| Technicals |
| Relative-Strength Index: |
47.3 |
N/A |
|
|
|
